ATE115862T1 - Tocole als impfstoffadjuvans. - Google Patents

Tocole als impfstoffadjuvans.

Info

Publication number
ATE115862T1
ATE115862T1 AT90200127T AT90200127T ATE115862T1 AT E115862 T1 ATE115862 T1 AT E115862T1 AT 90200127 T AT90200127 T AT 90200127T AT 90200127 T AT90200127 T AT 90200127T AT E115862 T1 ATE115862 T1 AT E115862T1
Authority
AT
Austria
Prior art keywords
vaccines
tocole
vaccine adjuvant
adjuvant
tocols
Prior art date
Application number
AT90200127T
Other languages
English (en)
Inventor
Lammert Cornelius
Eric Onno Rijke
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE115862T1 publication Critical patent/ATE115862T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90200127T 1989-02-04 1990-01-18 Tocole als impfstoffadjuvans. ATE115862T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8900277 1989-02-04

Publications (1)

Publication Number Publication Date
ATE115862T1 true ATE115862T1 (de) 1995-01-15

Family

ID=19854075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90200127T ATE115862T1 (de) 1989-02-04 1990-01-18 Tocole als impfstoffadjuvans.

Country Status (15)

Country Link
US (2) US5650155A (de)
EP (1) EP0382271B1 (de)
JP (1) JP2892739B2 (de)
KR (1) KR0162646B1 (de)
CN (1) CN1056085C (de)
AT (1) ATE115862T1 (de)
AU (1) AU633043B2 (de)
CA (1) CA2008856C (de)
DE (1) DE69015222T2 (de)
DK (1) DK0382271T3 (de)
ES (1) ES2068989T3 (de)
GR (1) GR3015438T3 (de)
HU (1) HU206989B (de)
NZ (1) NZ232354A (de)
ZA (1) ZA90512B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5919466A (en) * 1993-10-01 1999-07-06 Gerbu Biotechnik Gmbh Method for improving the yield of immunoantibodies in the vaccination of animals and humans
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
AU755502C (en) * 1999-03-24 2003-08-14 Secretary Of State For Defence, The Immunostimulants
PT2266603E (pt) 2000-10-18 2012-11-02 Glaxosmithkline Biolog Sa Vacinas tumorais
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
US20140248273A1 (en) 2001-09-08 2014-09-04 Jos van Strijp Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)
EP1741438A4 (de) * 2004-04-22 2009-08-26 Dainippon Sumitomo Pharma Co Pharmazeutisches präparat mit einer bakterienzellwand-skelett-komponente
HUE027837T2 (en) 2005-03-23 2016-11-28 Glaxosmithkline Biologicals Sa Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response
PL1926496T3 (pl) * 2005-09-09 2014-02-28 Intervet Int Bv Szczepionka przeciw PCV-2
DK179025B1 (da) 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
KR101541383B1 (ko) 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
WO2009027412A1 (en) 2007-08-28 2009-03-05 Universite De Liege A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi
US7741418B2 (en) * 2007-12-31 2010-06-22 Bridgestone Corporation Process for producing polydienes
JP5749642B2 (ja) 2008-04-16 2015-07-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
UA100047C2 (ru) * 2008-04-18 2012-11-12 Интервет Интернешонал Б.В. Вакцина для защиты от lawsonia intracellularis
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8277814B2 (en) 2008-04-28 2012-10-02 Intervet International B.V. Avian Astrovirus
WO2010017330A1 (en) * 2008-08-06 2010-02-11 Novartis Ag Microparticles for use in immunogenic compositions
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
US20110293660A1 (en) 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
EP2437753B1 (de) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5774010B2 (ja) 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスのための免疫拡散アッセイ
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
CN102946900A (zh) 2010-03-11 2013-02-27 免疫设计公司 用于大流行流感的疫苗
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
US20130039943A1 (en) 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
AU2011315447A1 (en) 2010-10-15 2013-05-09 Glaxosmithkline Biologicals S.A. Cytomegalovirus gB antigen
EP2629794B1 (de) 2010-10-18 2017-06-07 Intervet International B.V. Durch den truthahn-herpesvirus vektorisierter impfstoff gegen vogelgrippe bei geflügel
EP3593813A1 (de) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenzusammensetzung
JP5980810B2 (ja) 2010-12-29 2016-09-07 インターベット インターナショナル ベー． フェー． イヌバベシア症ワクチン抗原
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
RS61261B1 (sr) 2011-12-30 2021-01-29 Gesval S A Rekombinantni koi herpesvirus (khv) i vakcina za prevenciju bolesti prouzrokovane khv
WO2013113865A1 (en) 2012-02-03 2013-08-08 The Pirbright Institute Eimeria vector vaccine for campylobacter jejuni
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
EP3513806B1 (de) 2012-12-05 2023-01-25 GlaxoSmithKline Biologicals SA Immunogene zusammensetzung
CA2907571A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
RU2677347C2 (ru) 2013-03-29 2019-01-16 Интервет Интернэшнл Б.В. Вакцина против клещей рода rhipicephalus
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CN105247043A (zh) 2013-05-31 2016-01-13 英特维特国际股份有限公司 鳞片脱落疾病(sdd)致病病毒及其衍生物
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA2920934C (en) 2013-08-30 2022-12-06 Glaxosmithkline Biologicals S.A. Large scale production of viruses in cell culture
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US20160030459A1 (en) 2014-01-21 2016-02-04 Immune Design Corp. Compositions and methods for treating allergic conditions
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
DK3160500T3 (da) 2014-06-25 2019-11-11 Glaxosmithkline Biologicals Sa Clostridium difficile immunogen sammensætning
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
WO2016096688A1 (en) 2014-12-16 2016-06-23 Glaxosmithkline Biologicals S.A. A method for a large scale virus purification
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
DK3558351T3 (da) * 2016-12-23 2022-03-21 Intervet Int Bv Kombinationsvaccine til svin
CA3066915A1 (en) 2017-06-11 2018-12-20 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111511395B (zh) 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
BR112020011044A2 (pt) 2017-12-04 2020-11-17 Intervet International B.V. vacinação com partículas de replicon e adjuvante de óleo
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
WO2020044267A1 (en) 2018-08-29 2020-03-05 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
EP3662929A1 (de) 2018-12-07 2020-06-10 IDT Biologika GmbH Rekombinantes koi-herpesvirus (khv) und diva-impfstoff zur vorbeugung und/oder behandlung von khv-bedingten erkrankungen
AU2020318680A1 (en) 2019-07-21 2022-02-17 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
EP4004018A1 (de) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modifizierte humane cytomegalovirus-proteine
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
KR102617710B1 (ko) 2020-08-05 2024-01-25 주식회사 이노헨스 기판 처리장치
EP4255919A2 (de) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donorstrang-komplementierte fimh
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie
JP2024536600A (ja) 2021-10-25 2024-10-04 インターベット インターナショナル ベー． フェー． ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
AU596581B2 (en) * 1986-04-15 1990-05-10 Sansho Seiyaku Co., Ltd. Topical agents for inhibiting the melanin generation
ZA872532B (en) * 1986-04-21 1987-11-25 Akzo Nv Combined vaccine
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines

Also Published As

Publication number Publication date
US5667784A (en) 1997-09-16
KR900012630A (ko) 1990-09-01
JPH02250835A (ja) 1990-10-08
KR0162646B1 (ko) 1998-12-01
EP0382271A1 (de) 1990-08-16
DE69015222T2 (de) 1995-05-04
CA2008856C (en) 2001-06-19
ZA90512B (en) 1990-11-28
US5650155A (en) 1997-07-22
AU4897590A (en) 1990-08-09
DK0382271T3 (da) 1995-05-01
HUT56285A (en) 1991-08-28
CN1056085C (zh) 2000-09-06
CN1044594A (zh) 1990-08-15
JP2892739B2 (ja) 1999-05-17
HU206989B (en) 1993-03-01
NZ232354A (en) 1991-09-25
EP0382271B1 (de) 1994-12-21
DE69015222D1 (de) 1995-02-02
ES2068989T3 (es) 1995-05-01
AU633043B2 (en) 1993-01-21
GR3015438T3 (en) 1995-06-30
HU900653D0 (en) 1990-04-28
CA2008856A1 (en) 1990-08-04

Similar Documents

Publication Publication Date Title
ATE115862T1 (de) Tocole als impfstoffadjuvans.
LU91485I2 (fr) Vaccin adjuvant grippal dans lequel l'adjuvant estune émulsion huile-dans-eau comprenant du squalèn e, du DL-a-tocophérol et du polysorbate 80
ATE95425T1 (de) Impfstofformulierung.
ES2092306T3 (es) Adyuvante para vacunas.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
DK0764029T4 (da) Proteinadjuvanser
ES2138588T3 (es) Composiciones de vacunas que contienen liposomas.
NL300184I1 (nl) Acellulair vaccin.
SU1713152A1 (ru) Адъювант для ящурной вакцины

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time